Proficio Capital Partners LLC Acquires New Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Proficio Capital Partners LLC bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,631 shares of the company's stock, valued at approximately $1,689,000.

Other large investors also recently modified their holdings of the company. Martingale Asset Management L P lifted its holdings in Prestige Consumer Healthcare by 0.4% in the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company's stock worth $2,666,000 after buying an additional 140 shares during the period. Horizon Kinetics Asset Management LLC lifted its holdings in Prestige Consumer Healthcare by 4.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company's stock worth $234,000 after buying an additional 150 shares during the period. Huntington National Bank lifted its holdings in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock worth $108,000 after purchasing an additional 220 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $27,000. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PBH has been the subject of several analyst reports. DA Davidson raised their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average price target of $92.60.

Remove Ads

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded up $2.01 during trading hours on Friday, hitting $89.10. The company's stock had a trading volume of 604,737 shares, compared to its average volume of 328,521. Prestige Consumer Healthcare Inc. has a 12 month low of $62.35 and a 12 month high of $89.65. The company's 50 day simple moving average is $80.80 and its two-hundred day simple moving average is $77.88. The company has a market cap of $4.41 billion, a P/E ratio of 20.87, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.